Canaan reels in a jum­bo $800M fund with a big fo­cus on a new wave of biotech star­tups

In the lat­est sign of the leviathan ap­petite ven­ture in­vestors have for new tech­nol­o­gy, Canaan Part­ners — one of the busiest play­ers in biotech — has raised a firm-record $800 mil­lion fund to dri­ve a new wave of bets in the biz.

The Sil­i­con Val­ley-based Canaan has many in­ter­ests — fin­tech, mar­ket­places, en­ter­prise — with a spe­cial place in the port­fo­lio for a big chunk of bio­phar­ma. Known as a reg­u­lar in seed fi­nanc­ings and Se­ries A rounds, Canaan likes to get in ear­ly.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN